NewcelX Ltd. (NCEL) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

$17.44M

MomentumView details →

1D Return

−3.28%

YTD Return

+74.21%

RSI (14)

46.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

$17.44M

RSI (14)

46.6

MomentumView details →

1D Return

−3.28%

YTD Return

+74.21%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

1.99%

ROA (TTM)

1.26%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

+70.03%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+91.79%

EBITDA YoY

+75.27%

EarningsView details →

EPS (Actual)

−$0.00

EPS Surprise

100.00%

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

97.24%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

0.76x

Quick Ratio

0.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

144065.00

Op. CF (TTM)

−6.34M

Next earningsMar 3, 2027 →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.35d ago

Similar companies

Psyence Biomedical Ltd.PBM Pluri Inc.PLUR Tempest Therapeutics, Inc.TPST NeuroSense Therapeutics Ltd.NRSN BioVie Inc.BIVI Sensei Biotherapeutics, Inc.SNSE Find similar companies →

Latest newsMore news →

NewcelX priced a $1.4 million private equity financing at a 20% premium to support its lead Type 1 Diabetes program.35d ago